Paromomycin: A potential dual targeted drug effectively inhibits both spike (S1) and main protease of COVID-19

• DOI: 10.1016/j.ijid.2020.06.063
• Publication Date: 2020-06-21T14:29:04Z
• Authors: Asma Tariq; Rana Muhammad Mateen; Muhammad Sohail A...; Mahjabeen Saleem
• Keywords: Paromomycin; Coronavirus; Drug repositioning

ObjectivesWith the increasing number of people suffering from coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome 2 (SARS-CoV-2), there is a dire need to look for effective remedies against this pandemic. Drug repurposing seems be solution current situation.MethodsIn quest find potential drug virus, 15 antimalarial drugs (including chloroquine) and 2413 US Food Administration-approved were investigated activity both protease spike proteins SARS-CoV-2 using an in silico approach. Molecular docking analysis followed molecular dynamics simulation was performed estimate binding stability complexes.ResultsThis study identified single – paromomycin with two targets SARS-CoV-2, i.e., protein (S1) domain. Paromomycin found have strong affinity coronavirus. The results also showed that no exhibited either S1 or protease.ConclusionsThis may dual targeting coronavirus, as it binds not only domain virion, but domain, high stability. Furthermore, none receptor (RBD).